We know they’re common and annoying, and in the immunocompromised or the unlucky, sometimes deadly. But three years after COVID-19 rocked the world, are we now learning viruses are more of a threat than we imagined? Do they all “go long”?
Experts across Fred Hutch gave their reads on what's to come in 2022, including technological advancements, new standards of care for people with cancer and progress against infectious disease.
In 2021, the continuing COVID-19 pandemic challenged our daily lives but also sparked incredible scientific advancements as Fred Hutch researchers worked to understand the evolving SARS-CoV-2 virus and develop ways to stop the disease.
In 2021, the continuing COVID-19 pandemic challenged our daily lives but also sparked incredible scientific advancements as Fred Hutch researchers worked to understand the evolving SARS-CoV-2 virus and develop ways to stop the disease.
New study highlights lack of diversity and inclusion in vaccine clinical trials
Analysis shows certain racial/ethnic groups and older people aren’t being adequately represented and trial reporting guidelines aren’t being followed Anthony Jackson, security coordinator for Fred Hutchinson Cancer Research Center, receives a dose of the new Pfizer-BioNTech COVID-19 vaccine on Jan. 19, 2021, at a new vaccine clinic set up on the Fred Hutch campus. Robert Hood
SEATTLE February 19, 2021 A team of scientific experts from across the U.S. and Puerto Rico are advocating for increased diversity in vaccine trials after publishing a new report that highlights a decade’s worth of disparities. The new study, published in JAMA Network Open, found that among U.S.-based vaccine clinical trials, people who are Black/African American, American Indian/Alaska Native, Hispanic/Latino and age 65 and older were the most underrepresented groups. Conversely, adult women